Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02051764 · ClinicalTrials.gov registry record · Phase 2
Imaging Characteristics of a Follow-up 18F-AV-1451 Scan
A Phase 2 study, sponsored by Avid Radiopharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT02051764: Clinical Trial Phase 2 study, sponsored by Avid Radiopharmaceuticals.
NCT02051764 is a Phase 2 study that was terminated before completion, run by Avid Radiopharmaceuticals. The registered enrollment target is 44 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02051764, a Phase 2 study, was terminated before completion, sponsored by Avid Radiopharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study will evaluate the imaging characteristics of flortaucipir in subjects with a previous flortaucipir scan in order to assess the rate of change of tau deposition over time.
Primary Outcome
Rate of tau deposition change as measured by flortaucipir standardized uptake value ratio (SUVr). For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
Interventions
- DRUG Flortaucipir F18
- PROCEDURE Brain PET Scan
- DRUG Florbetapir F 18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Why NCT02051764 stopped before completion
NCT02051764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 3 interventions - of which Flortaucipir F18 is the first listed.
NCT02051764 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02051764 about?
NCT02051764 is a clinical study titled "Imaging Characteristics of a Follow-up 18F-AV-1451 Scan". This study will evaluate the imaging characteristics of flortaucipir in subjects with a previous flortaucipir scan in order to assess the rate of change of tau deposition over time.
What is the current status of trial NCT02051764?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2014-05. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02051764?
The interventions under investigation include: Flortaucipir F18 (DRUG), Brain PET Scan (PROCEDURE), Florbetapir F 18 (DRUG).
Who is sponsoring clinical trial NCT02051764?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02051764's enrollment target sits among peer trials
44 1322nd of 2000 higher than 669 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia